All Outputs (4)

Modified-release morphine or placebo for chronic breathlessness: the MABEL trial protocol (2023)
Journal Article
Date, K., Williams, B., Cohen, J., Chaudhuri, N., Bajwah, S., Pearson, M., Higginson, I., Norrie, J., Keerie, C., Tuck, S., Hall, P., Currow, D., Fallon, M., & Johnson, M. (2023). Modified-release morphine or placebo for chronic breathlessness: the MABEL trial protocol. ERJ Open Research, 9(4), Article 00167. https://doi.org/10.1183/23120541.00167-2023

Chronic breathlessness, a persistent and disabling symptom despite optimal treatment of underlying causes, is a frightening symptom with serious and widespread impact on patients and their carers. Clinical guidelines support the use of morphine for t... Read More about Modified-release morphine or placebo for chronic breathlessness: the MABEL trial protocol.

Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial (2018)
Journal Article
Hutchinson, A., Rees, S., Young, A., Maraveyas, A., Date, K., & Johnson, M. J. (2019). Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial. Palliative medicine, 33(5), 510-517. https://doi.org/10.1177/0269216318815377

Background: Cancer patients have a four- to fivefold greater risk of thrombosis than the general population. Recommended treatment for cancer-associated thrombosis is 3–6 months of low-molecular-weight heparin. The ‘select-d’ trial is an open-label,... Read More about Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial.

CAMERA - complete assessment of elderly patients with cancer: A non-randomised feasibility study (2018)
Journal Article
Jackson, G., Gabe, R., Johnson, M., Date, K., Harman, D., Maraveyas, A., Roy, R., & Lind, M. J. (2019). CAMERA - complete assessment of elderly patients with cancer: A non-randomised feasibility study. Journal of Geriatric Oncology, 10(1), 175-177. https://doi.org/10.1016/j.jgo.2018.07.005

One of the primary risk factors in the development of cancer is older age. The demographic shift to an ageing population has given rise to an increased number of older patients with cancer. The extreme heterogeneity within this population renders app... Read More about CAMERA - complete assessment of elderly patients with cancer: A non-randomised feasibility study.

Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer (2017)
Journal Article
Date, K., Ettelaie, C., & Maraveyas, A. (2017). Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer. Journal of thrombosis and haemostasis : JTH, 15(12), 2289-2299. https://doi.org/10.1111/jth.13871

© 2017 International Society on Thrombosis and Haemostasis Summary: Cancer is associated with an increased risk of venous thromboembolism (VTE); the exact mechanisms for the induction of VTE remain to be fully elucidated, but it is widely acknowledge... Read More about Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer.